Apixaban Management Before Port Placement

Preoperative Discontinuation Protocol

Hold apixaban for a minimum of 48 hours before port placement in patients with normal renal function (CrCl >50 mL/min) 1, 2
For patients with impaired renal function (CrCl 30-50 mL/min), extend the hold to 72 hours (3 days) to account for reduced drug clearance 3, 4, 5

Always assess creatinine clearance using the Cockcroft-Gault formula before determining hold duration 3, 4, 5
CrCl >50 mL/min: 48-hour hold minimum 2
CrCl 30-50 mL/min: 72-hour (3-day) hold minimum 4

Check for P-glycoprotein and CYP3A4 inhibitors that may prolong apixaban clearance 3, 4, 5
If the patient is taking strong P-gp or CYP3A4 inhibitors, consider extending the hold period by an additional 24 hours 4

Do not use heparin bridging for port placement 3, 5, 1
Bridging anticoagulation increases bleeding risk without reducing thrombotic events in most patients 1, 2

Resume apixaban at least 6 hours after port placement once adequate hemostasis is confirmed 1, 2
For procedures with higher bleeding risk, consider delaying resumption to 24-48 hours postoperatively 3, 5

Do not assume 24 hours is sufficient—port placement requires at least 48 hours for standard patients 1, 2
Do not forget to assess renal function—impaired clearance necessitates longer hold times 3, 4, 5
Do not bridge with heparin routinely—this increases bleeding without benefit 1, 2
Do not resume apixaban too early—confirm hemostasis before restarting anticoagulation 1
Do not ignore drug interactions—P-gp and CYP3A4 inhibitors require extended hold periods 3, 4, 5

For very high bleeding risk procedures, such as neuraxial anesthesia/puncture or intracranial neurosurgery, discontinue apixaban 72 hours before surgery, as recommended by the Anaesthesia journal 6

The Anaesthesia journal recommends against using heparin bridging, as it increases major bleeding risk without reducing stroke or systemic embolism, and preoperative bridging with unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) is not recommended 6

According to the Anaesthesia journal, there is no reason to routinely measure apixaban concentration before procedures, and standard coagulation tests (INR, aPTT) are not useful for monitoring apixaban effect 6